TVTX
Travere Therapeutics, Inc.
Price Chart
Latest Quote
$53.38
-0.42 (-0.78%)
Current Price
| Previous Close | $53.80 |
| Open | $53.88 |
| Day High | $54.38 |
| Day Low | $52.72 |
| Volume | 1,739,631 |
Stock Information
| Shares Outstanding | 92.99M |
| Total Debt | $327.66M |
| Cash Equivalents | $264.68M |
| Revenue | $536.20M |
| Net Income | $-45.64M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.03B |
| EPS (TTM) | $-0.50 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.03B |
| Sales | $536.20M |
| Income | $-45.64M |
| Book/sh | $1.07 |
| Cash/sh | $2.85 |
| Employees | 497 |
Financial Ratios
| Quick Ratio | 2.82 |
| Current Ratio | 3.13 |
| Debt/Eq | 331.88 |
Returns & Margins
| ROA | -6.46% |
| ROE | -69.38% |
| Gross Margin | 55.95% |
| Operating Margin | -29.02% |
| Profit Margin | -4.00% |
Ownership
| Insider Ownership | 0.80% |
| Institutional Ownership | 113.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 11.15 |
| P/S | 9.39 |
| P/B | 50.69 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $56.71 |
Technical Indicators
| SMA20 | $47.48 |
| SMA50 | $43.33 |
| SMA200 | $33.43 |
| RSI | 65.03 |
| ATR | 2.5132 |
| Shares Float | 86.99M |
| Short Float | 19.86% |
| Short Ratio | 5.70 |
| Volatility | 1.14 |
| Rel Volume | 0.68 |
Performance History
| Week | +15.83% |
| Month | +26.23% |
| Quarter | +100.82% |
| 6 Months | +55.75% |
| YTD | +36.99% |
| Year | +268.80% |
| 3 Years | +215.87% |
| 5 Years | +270.82% |
| 10 Years | +208.49% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $54.14 | 1,347,900 |
| 2026-06-16 | $53.38 | 2,130,800 |
| 2026-06-15 | $53.80 | 2,105,900 |
| 2026-06-12 | $52.04 | 2,389,000 |
| 2026-06-11 | $48.91 | 2,639,300 |
| 2026-06-10 | $46.74 | 1,632,100 |
| 2026-06-09 | $48.57 | 2,621,900 |
| 2026-06-08 | $47.08 | 1,943,700 |
| 2026-06-05 | $45.81 | 2,910,000 |
| 2026-06-04 | $46.18 | 1,609,900 |
| 2026-06-03 | $45.20 | 1,769,800 |
| 2026-06-02 | $42.96 | 2,533,700 |
| 2026-06-01 | $45.04 | 1,382,200 |
| 2026-05-29 | $47.18 | 2,177,200 |
| 2026-05-28 | $47.76 | 1,854,500 |
| 2026-05-27 | $47.76 | 3,113,100 |
| 2026-05-26 | $44.29 | 1,808,500 |
| 2026-05-22 | $44.43 | 803,400 |
| 2026-05-21 | $44.74 | 1,325,400 |
| 2026-05-20 | $43.49 | 1,596,100 |
| 2026-05-19 | $42.26 | 1,294,000 |
| 2026-05-18 | $42.89 | 1,774,800 |
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
đ° Latest News
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-13T20:45:52Z
3 Stocks That May Be Priced Below Their Estimated Value In June 2026
Simply Wall St. âĸ 2026-06-08T17:38:00Z
Extreme Networks And 2 Other Stocks That Could Be Trading Below Their Estimated Value
Simply Wall St. âĸ 2026-06-03T17:38:02Z
3 Stocks That May Be Priced Below Their Estimated Worth In June 2026
Simply Wall St. âĸ 2026-06-03T11:38:08Z
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside
Stocktwits âĸ 2026-06-02T18:14:15Z
Discover 3 Stocks That May Be Trading Below Their Estimated Value
Simply Wall St. âĸ 2026-05-27T17:38:29Z
Dow Jones Leader Amazon, AI Stock Quanta, Monster Beverage In Or Near Buy Zones
Investor's Business Daily âĸ 2026-05-26T17:25:19Z
3 Stocks That May Be Undervalued By The Market In May 2026
Simply Wall St. âĸ 2026-05-21T17:38:30Z
Fifth Third Bancorp And 2 Stocks Possibly Undervalued For Consideration
Simply Wall St. âĸ 2026-05-21T11:39:04Z
3 Stocks Estimated To Be Trading Below Intrinsic Value By 11.4% To 38.4%
Simply Wall St. âĸ 2026-05-20T17:38:07Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $10,339,000 | $7,744,000 | $11,450,000 | $4,420,000 |
| Cost Of Revenue | $10,339,000 | $7,744,000 | $11,450,000 | $4,420,000 |
| Total Revenue | $490,728,000 | $233,175,000 | $145,238,000 | $109,460,000 |
| Operating Revenue | $490,728,000 | $233,175,000 | $145,238,000 | $109,460,000 |
| Expenses | ||||
| Interest Expense | $10,748,000 | $11,182,000 | $11,334,000 | $11,014,000 |
| Total Expenses | $553,552,000 | $554,564,000 | $521,982,000 | $429,273,000 |
| Other Income Expense | $11,578,000 | $-5,756,000 | $-9,800,000 | $-6,604,000 |
| Other Non Operating Income Expenses | $11,578,000 | $-3,318,000 | $1,594,000 | $974,000 |
| Net Non Operating Interest Income Expense | $1,973,000 | $6,635,000 | $10,434,000 | $-4,738,000 |
| Interest Expense Non Operating | $10,748,000 | $11,182,000 | $11,334,000 | $11,014,000 |
| Operating Expense | $543,213,000 | $546,820,000 | $510,532,000 | $424,853,000 |
| General And Administrative Expense | $337,202,000 | $264,119,000 | $265,542,000 | $197,520,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-50,261,000 | $-320,630,000 | $-376,333,000 | $-331,468,000 |
| Net Interest Income | $1,973,000 | $6,635,000 | $10,434,000 | $-4,738,000 |
| Interest Income | $12,721,000 | $17,817,000 | $21,768,000 | $6,276,000 |
| Normalized Income | $-50,261,000 | $-318,703,980 | $-367,331,740 | $-325,481,380 |
| Net Income From Continuing And Discontinued Operation | $-25,546,000 | $-321,545,000 | $-111,399,000 | $-278,482,000 |
| Total Operating Income As Reported | $-62,824,000 | $-323,827,000 | $-388,138,000 | $-319,813,000 |
| Net Income Common Stockholders | $-25,546,000 | $-321,545,000 | $-111,399,000 | $-278,482,000 |
| Net Income | $-25,546,000 | $-321,545,000 | $-111,399,000 | $-278,482,000 |
| Net Income Including Noncontrolling Interests | $-25,546,000 | $-321,545,000 | $-111,399,000 | $-278,482,000 |
| Net Income Discontinuous Operations | $24,715,000 | $-915,000 | $264,934,000 | $52,986,000 |
| Net Income Continuous Operations | $-50,261,000 | $-320,630,000 | $-376,333,000 | $-331,468,000 |
| Pretax Income | $-49,273,000 | $-320,510,000 | $-376,110,000 | $-331,155,000 |
| Special Income Charges | $0 | $-2,438,000 | $-11,394,000 | $-7,578,000 |
| Interest Income Non Operating | $12,721,000 | $17,817,000 | $21,768,000 | $6,276,000 |
| Operating Income | $-62,824,000 | $-321,389,000 | $-376,744,000 | $-319,813,000 |
| Gross Profit | $480,389,000 | $225,431,000 | $133,788,000 | $105,040,000 |
| Per Share | ||||
| Diluted EPS | $-0.29 | $-4.08 | $-1.50 | $-4.37 |
| Basic EPS | $-0.29 | $-4.08 | $-1.50 | $-4.37 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-511,980 | $-2,392,740 | $-1,591,380 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $22,218,000 | $-263,335,000 | $-314,852,000 | $-291,844,000 |
| Total Unusual Items | $0 | $-2,438,000 | $-11,394,000 | $-7,578,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-2,438,000 | $-11,394,000 | $-7,578,000 |
| Reconciled Depreciation | $60,743,000 | $43,555,000 | $38,530,000 | $20,719,000 |
| EBITDA (Bullshit earnings) | $22,218,000 | $-265,773,000 | $-326,246,000 | $-299,422,000 |
| EBIT | $-38,525,000 | $-309,328,000 | $-364,776,000 | $-320,141,000 |
| Diluted Average Shares | $89,211,813 | $78,888,861 | $74,267,418 | $63,758,515 |
| Basic Average Shares | $89,211,813 | $78,888,861 | $74,267,418 | $63,758,515 |
| Diluted NI Availto Com Stockholders | $-25,546,000 | $-321,545,000 | $-111,399,000 | $-278,482,000 |
| Tax Provision | $988,000 | $120,000 | $223,000 | $313,000 |
| Restructuring And Mergern Acquisition | $0 | $2,438,000 | $11,394,000 | $0 |
| Research And Development | $206,011,000 | $282,701,000 | $244,990,000 | $227,333,000 |
| Selling General And Administration | $337,202,000 | $264,119,000 | $265,542,000 | $197,520,000 |
| Other Gand A | $337,202,000 | $264,119,000 | $265,542,000 | $197,520,000 |
| Other Special Charges | - | - | - | $7,578,000 |
| Write Off | - | - | - | - |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,713,000 | $-44,144,000 | $96,320,000 | $-54,269,000 |
| Total Assets | $605,191,000 | $594,125,000 | $788,913,000 | $672,585,000 |
| Total Non Current Assets | $166,873,000 | $176,670,000 | $172,185,000 | $186,195,000 |
| Other Non Current Assets | $39,160,000 | $53,818,000 | $42,155,000 | $59,026,000 |
| Goodwill And Other Intangible Assets | $113,115,000 | $103,221,000 | $104,490,000 | $97,120,000 |
| Other Intangible Assets | $113,115,000 | $103,221,000 | $103,690,000 | $96,320,000 |
| Current Assets | $437,565,000 | $416,702,000 | $616,775,000 | $486,437,000 |
| Other Current Assets | $28,760,000 | $12,685,000 | $19,335,000 | $12,033,000 |
| Inventory | $5,875,000 | $6,200,000 | $9,410,000 | $4,523,000 |
| Receivables | $80,134,000 | $27,116,000 | $21,179,000 | $16,646,000 |
| Accounts Receivable | $80,134,000 | $27,116,000 | $21,179,000 | $16,646,000 |
| Cash Cash Equivalents And Short Term Investments | $322,796,000 | $370,701,000 | $566,851,000 | $450,245,000 |
| Cash And Cash Equivalents | $93,035,000 | $58,535,000 | $58,176,000 | $61,688,000 |
| Assets Held For Sale Current | - | - | $0 | $2,990,000 |
| Prepaid Assets | - | - | - | - |
| Taxes Receivable | - | - | - | - |
| Debt | ||||
| Net Debt | $218,689,000 | $320,453,000 | $319,087,000 | $313,857,000 |
| Total Debt | $328,733,000 | $401,584,000 | $404,784,000 | $407,488,000 |
| Long Term Debt And Capital Lease Obligation | $322,858,000 | $327,501,000 | $399,875,000 | $403,055,000 |
| Long Term Debt | $311,724,000 | $310,310,000 | $377,263,000 | $375,545,000 |
| Current Debt And Capital Lease Obligation | $5,875,000 | $74,083,000 | $4,909,000 | $4,433,000 |
| Current Debt | - | $68,678,000 | - | - |
| Other Current Borrowings | - | $68,678,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $490,363,000 | $535,048,000 | $588,103,000 | $629,734,000 |
| Total Non Current Liabilities Net Minority Interest | $330,459,000 | $334,297,000 | $410,195,000 | $487,571,000 |
| Other Non Current Liabilities | $7,601,000 | $6,796,000 | $10,320,000 | $9,385,000 |
| Current Liabilities | $159,904,000 | $200,751,000 | $177,908,000 | $142,163,000 |
| Other Current Liabilities | $3,194,000 | $17,106,000 | $5,237,000 | $12,722,000 |
| Payables And Accrued Expenses | $109,320,000 | $74,396,000 | $130,758,000 | $77,765,000 |
| Payables | $24,800,000 | $23,534,000 | $41,675,000 | $17,290,000 |
| Accounts Payable | $24,800,000 | $23,534,000 | $41,675,000 | $17,290,000 |
| Current Deferred Liabilities | - | $2,815,000 | $7,096,000 | $11,976,000 |
| Liabilities Heldfor Sale Non Current | - | - | $0 | $64,200,000 |
| Non Current Deferred Liabilities | - | - | $1,835,000 | $10,931,000 |
| Other Payable | - | - | - | $13,486,000 |
| Equity | ||||
| Common Stock Equity | $114,828,000 | $59,077,000 | $200,810,000 | $42,851,000 |
| Total Equity Gross Minority Interest | $114,828,000 | $59,077,000 | $200,810,000 | $42,851,000 |
| Stockholders Equity | $114,828,000 | $59,077,000 | $200,810,000 | $42,851,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,189,000 | $-80,000 | $-1,456,000 | $-2,907,000 |
| Other Equity Adjustments | $-1,189,000 | $-80,000 | $-1,456,000 | $-2,907,000 |
| Retained Earnings | $-1,472,713,000 | $-1,447,167,000 | $-1,125,622,000 | $-1,014,223,000 |
| Other | ||||
| Ordinary Shares Number | $90,922,868 | $87,452,835 | $75,367,117 | $64,290,570 |
| Share Issued | $90,922,868 | $87,452,835 | $75,367,117 | $64,290,570 |
| Tangible Book Value | $1,713,000 | $-44,144,000 | $96,320,000 | $-54,269,000 |
| Invested Capital | $426,552,000 | $438,065,000 | $578,073,000 | $418,396,000 |
| Working Capital | $277,661,000 | $215,951,000 | $438,867,000 | $344,274,000 |
| Capital Lease Obligations | $17,009,000 | $22,596,000 | $27,521,000 | $31,943,000 |
| Total Capitalization | $426,552,000 | $369,387,000 | $578,073,000 | $418,396,000 |
| Additional Paid In Capital | $1,588,721,000 | $1,506,315,000 | $1,327,881,000 | $1,059,975,000 |
| Capital Stock | $9,000 | $9,000 | $7,000 | $6,000 |
| Common Stock | $9,000 | $9,000 | $7,000 | $6,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $11,134,000 | $17,191,000 | $22,612,000 | $27,510,000 |
| Current Capital Lease Obligation | $5,875,000 | $5,405,000 | $4,909,000 | $4,433,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $41,515,000 | $35,166,000 | $29,908,000 | $35,267,000 |
| Current Accrued Expenses | $84,520,000 | $50,862,000 | $89,083,000 | $60,475,000 |
| Net PPE | $14,598,000 | $19,631,000 | $25,540,000 | $30,049,000 |
| Accumulated Depreciation | $-10,098,000 | $-8,755,000 | $-7,443,000 | $-5,195,000 |
| Gross PPE | $24,696,000 | $28,386,000 | $32,983,000 | $35,244,000 |
| Leases | $8,992,000 | $9,370,000 | $9,692,000 | $9,180,000 |
| Machinery Furniture Equipment | $5,128,000 | $4,721,000 | $5,061,000 | $4,987,000 |
| Buildings And Improvements | $10,576,000 | $14,295,000 | $18,061,000 | $21,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $229,761,000 | $312,166,000 | $508,675,000 | $388,557,000 |
| Current Deferred Revenue | - | $2,815,000 | $7,096,000 | $11,976,000 |
| Goodwill | - | $800,000 | $800,000 | $800,000 |
| Construction In Progress | - | $0 | $169,000 | $77,000 |
| Non Current Deferred Revenue | - | - | $1,835,000 | $10,931,000 |
| Finished Goods | - | - | - | $2,126,000 |
| Work In Process | - | - | - | $0 |
| Raw Materials | - | - | - | $2,397,000 |
| Other Properties | - | - | - | - |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-20,373,000 | $-338,687,000 | $-321,612,000 | $-214,657,000 |
| Operating Activities | ||||
| Operating Cash Flow | $37,784,000 | $-237,475,000 | $-280,021,000 | $-186,291,000 |
| Cash From Discontinued Operating Activities | $0 | $-7,451,000 | $45,336,000 | $74,555,000 |
| Cash Flow From Continuing Operating Activities | $37,784,000 | $-230,024,000 | $-325,357,000 | $-260,846,000 |
| Operating Gains Losses | - | - | - | $7,578,000 |
| Investing Activities | ||||
| Capital Expenditure | $-58,157,000 | $-101,212,000 | $-41,591,000 | $-28,366,000 |
| Investing Cash Flow | $27,892,000 | $99,325,000 | $55,776,000 | $-32,553,000 |
| Cash From Discontinued Investing Activities | $0 | $0 | $207,402,000 | $0 |
| Cash Flow From Continuing Investing Activities | $27,892,000 | $99,325,000 | $-151,626,000 | $-32,553,000 |
| Net Other Investing Changes | $-404,000 | $-40,000 | $-668,000 | $-791,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $134,738,000 | $191,198,000 | $19,545,000 |
| Financing Cash Flow | $-33,467,000 | $139,422,000 | $218,752,000 | $117,573,000 |
| Cash From Discontinued Financing Activities | $0 | $0 | $-1,382,000 | $-2,479,000 |
| Cash Flow From Continuing Financing Activities | $-33,467,000 | $139,422,000 | $220,134,000 | $120,052,000 |
| Net Other Financing Charges | $-2,100,000 | $-2,100,000 | $-2,100,000 | $-11,982,000 |
| Net Common Stock Issuance | $0 | $134,738,000 | $191,198,000 | $19,545,000 |
| Common Stock Issuance | $0 | $134,738,000 | $191,198,000 | $19,545,000 |
| Other | ||||
| Repayment Of Debt | $-68,904,000 | $0 | $0 | $-211,324,000 |
| Interest Paid Supplemental Data | $8,838,000 | $8,838,000 | $8,838,000 | $10,159,000 |
| End Cash Position | $93,035,000 | $58,535,000 | $58,176,000 | $61,688,000 |
| Beginning Cash Position | $58,535,000 | $58,176,000 | $61,688,000 | $165,753,000 |
| Effect Of Exchange Rate Changes | $2,291,000 | $-913,000 | $1,981,000 | $-2,794,000 |
| Changes In Cash | $32,209,000 | $1,272,000 | $-5,493,000 | $-101,271,000 |
| Proceeds From Stock Option Exercised | $37,537,000 | $6,784,000 | $31,036,000 | $7,563,000 |
| Net Issuance Payments Of Debt | $-68,904,000 | $0 | $0 | $104,926,000 |
| Net Long Term Debt Issuance | $-68,904,000 | $0 | $0 | $104,926,000 |
| Long Term Debt Payments | $-68,904,000 | $0 | $0 | $-211,324,000 |
| Net Investment Purchase And Sale | $86,453,000 | $200,577,000 | $-109,367,000 | $-3,396,000 |
| Sale Of Investment | $323,595,000 | $326,334,000 | $334,575,000 | $381,993,000 |
| Purchase Of Investment | $-237,142,000 | $-125,757,000 | $-443,942,000 | $-385,389,000 |
| Net Intangibles Purchase And Sale | $-58,157,000 | $-101,212,000 | $-41,591,000 | $-28,366,000 |
| Purchase Of Intangibles | $-58,157,000 | $-101,212,000 | $-41,591,000 | $-28,366,000 |
| Change In Working Capital | $-13,997,000 | $-63,020,000 | $-25,475,000 | $875,000 |
| Change In Other Working Capital | $-3,437,000 | $-7,065,000 | $-16,765,000 | $-13,913,000 |
| Change In Other Current Liabilities | $-9,700,000 | $5,646,000 | $-418,000 | $-1,609,000 |
| Change In Payables And Accrued Expense | $28,755,000 | $-48,624,000 | $47,084,000 | $24,236,000 |
| Change In Accrued Expense | $28,840,000 | $-31,061,000 | $22,321,000 | $22,181,000 |
| Change In Payable | $-85,000 | $-17,563,000 | $24,763,000 | $2,055,000 |
| Change In Account Payable | $-85,000 | $-17,563,000 | $24,763,000 | $2,055,000 |
| Change In Prepaid Assets | $-7,658,000 | $-3,164,000 | $-4,657,000 | $-5,196,000 |
| Change In Inventory | $5,016,000 | $-3,771,000 | $-39,420,000 | $-1,209,000 |
| Change In Receivables | $-26,973,000 | $-6,042,000 | $-11,299,000 | $-1,434,000 |
| Changes In Account Receivables | $-27,822,000 | $-6,001,000 | $-11,264,000 | $-1,060,000 |
| Other Non Cash Items | $183,000 | $74,874,000 | $-1,908,000 | $2,968,000 |
| Stock Based Compensation | $44,868,000 | $36,913,000 | $44,246,000 | $38,143,000 |
| Provisionand Write Offof Assets | $684,000 | $2,819,000 | $3,039,000 | $1,039,000 |
| Amortization Of Securities | $-4,436,000 | $-4,535,000 | $-7,456,000 | $-700,000 |
| Depreciation Amortization Depletion | $60,743,000 | $43,555,000 | $38,530,000 | $20,719,000 |
| Depreciation And Amortization | $60,743,000 | $43,555,000 | $38,530,000 | $20,719,000 |
| Net Income From Continuing Operations | $-50,261,000 | $-320,630,000 | $-376,333,000 | $-331,468,000 |
| Issuance Of Debt | - | $0 | $0 | $316,250,000 |
| Long Term Debt Issuance | - | $0 | $0 | $316,250,000 |
| Net PPE Purchase And Sale | - | - | $-668,000 | $-191,000 |
| Purchase Of PPE | - | - | $-668,000 | $-191,000 |
| Income Tax Paid Supplemental Data | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-06-14